Yonhap Infomax NewsFeb 6
Kolon Group reduces financial risk from Invossa gene therapy as legal challenges ease, boosting corporate value with the drug’s U.S. market potential nearing $7.5 billion.
#YonhapInfomax #KolonGroup #Invossa #LegalRisks #TGC #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104258
Kolon Eases Financial Burden from Invossa Development as Legal Hurdles Gradually Clear

Kolon Group reduces financial risk from Invossa gene therapy as legal challenges ease, boosting corporate value with the drug’s U.S. market potential nearing $7.5 billion.

Yonhap Infomax